Full Press Release Details
Therapeutics and Amplitude Healthcare Acquisition Corporation Announce
REDWOOD CITY, Calif., and New York - September 20, 2021, Jasper
Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporation
(Nasdaq: AMHCU), a special purpose acquisition company (SPAC) sponsored by affiliates of Avego Management, LLC and Metalmark Capital,
today announced that Lawrence Klein, Ph.D., and Chris Nolet will be appointed to Jasper Therapeutics' board of directors, effective
upon closing of the pending merger between the parties. Mr. Nolet will assume the role of Audit Committee Chair.
"We are pleased to appoint Lawrence and Chris to the Jasper board
of directors to add additional expertise to the team in cellular and gene therapy development and to build a leading public biotechnology
company," said Bill Lis, executive chairman and chief executive officer of Jasper Therapeutics. "We look forward to their
input and guidance as we advance the clinical development of JSP191, our anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning
agent, and our novel engineered stem cell platform, which aims to expand the number of patients who could benefit from allogeneic and
autologous gene edited hematopoietic stem cell therapy."
Dr. Klein currently serves as chief operating officer at CRISPR Therapeutics,
where he previously served as senior vice president and head of strategy and business development. Before joining CRISPR, he was an associate
partner at McKinsey & Company, where he was a leader in the biotech practice and served a number of biotech companies on a wide range
of topics from strategy to operations. He earned a B.S. in biochemistry and physics from the University of Wisconsin-Madison and a Ph.D.
in biophysics from Stanford University.
Mr. Nolet has extensive experience as a long-time audit partner and
business advisor in the life sciences industry. He currently serves on the boards of three publicly-traded life science companies
and the board a life science industry organization. He is the former West Region Life Sciences Industry Leader and Partner at Ernst
& Young (EY), having retired in June 2019 after more than 38 years in the profession. In addition to serving clients, his responsibilities
included leading the West Region EY Life Sciences Industry Group and serving as a member of the Global EY Life Sciences Executive Leadership
Group, which established policies and operating strategies for the EY Life Sciences practice worldwide. Prior to joining EY, Mr. Nolet
was a partner at PricewaterhouseCoopers, where he led the life sciences
practice in the western U.S. He holds a B.S. in accounting from San Diego State University and is
a certified public accountant in California (retired).
About Jasper Therapeutics
Jasper Therapeutics is a biotechnology company focused on the development
of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking
programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem
cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective
curative allogeneic and autologous hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its
preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous
gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy
cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today.
For more information, please visit us at jaspertherapeutics.com.
About Amplitude Healthcare Acquisition Corporation
Amplitude was founded by Avego and Metalmark to seek innovative private
life sciences company acquisition targets. We leverage our management and board's reputation, experience, and track record of making
investments and creating value in the industry. We have a strong history of building and growing companies as constructive and trustworthy
partners. For more information, please visit: https://www.amplitudehealthcare.com.
Forward Looking Statements
This press release contains certain forward-looking
statements within the meaning of the federal securities laws with respect to the proposed business combination between Jasper Therapeutics,
Inc. and Amplitude Healthcare Acquisition Corporation, the proposed appointment of Lawrence Klein, Ph.D., and Chris Nolet to the Jasper
Therapeutics' board of directors, effective upon closing of the pending merger between the parties and Jasper Therapeutics'
products, technologies and prospects. These forward-looking statements generally are identified by the words "believe," "project,"
"expect," "anticipate," "estimate," "intend," "strategy," "future,"
"forecast," "opportunity," "plan," "may," "should," "will," "would,"
"will be," "will continue," "will likely result," and similar expressions (including the negative
versions of such words or expressions). Forward-looking statements are predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause
actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the
risk that the proposed business combination may not be completed in a timely manner or at all; (ii) the failure to satisfy the conditions
to the consummation of the proposed business combination; (iii) the effect of the announcement or pendency of the proposed business combination
on Jasper Therapeutics' business relationships, performance, and business generally; and (iv) the ability to implement business
plans, forecasts, and other expectations after the completion of the proposed business combination, and identify and realize additional
opportunities. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks
and uncertainties described in Amplitude Healthcare Acquisition Corporation final proxy statement/information statement/prospectus contained
in the Form S-4 registration statement described below, including those under "Risk Factors" therein, Quarterly Reports on
Form 10-Q and other documents filed by Amplitude Healthcare Acquisition Corporation from time to time with the U.S. Securities and Exchange
Commission (the "SEC"). These filings identify and address other important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Jasper Therapeutics,
Inc. and Amplitude Healthcare Acquisition Corporation assume no obligation and, except as required by law, do not intend to update or
revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Jasper Therapeutics,
Inc. nor Amplitude Healthcare Acquisition Corporation gives any assurance that either Jasper Therapeutics, Inc. or Amplitude Healthcare
Acquisition Corporation will achieve its expectations.
Additional Information and Where to Find It
In connection with the proposed business combination
between Jasper Therapeutics, Inc. and Amplitude Healthcare Acquisition Corporation, the registration statement on Form S-4 has been declared
effective by the SEC. That registration statement includes the related proxy statement and prospectus of Amplitude Healthcare Acquisition
Corporation with respect to Amplitude Healthcare Acquisition Corporation's special meeting of stockholders. Amplitude Healthcare
Acquisition Corporation's stockholders and other interested persons are advised to read the registration statement and the related
proxy statement/prospectus and any documents filed in connection therewith, as these materials will contain important information about
Jasper Therapeutics, Inc., Amplitude Healthcare Acquisition Corporation and the proposed business combination. The definitive proxy statement
and related materials have been mailed to Amplitude Healthcare Acquisition Corporation's stockholders who were holders of record
as of the close of business on August 20, 2021 .
Investors and security holders may obtain free
copies of the proxy statement/information statement/prospectus and all other relevant documents filed with the SEC by Amplitude Healthcare
Acquisition Corporation through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by Amplitude Healthcare
Acquisition Corporation may be obtained free of charge by directing a request to Amplitude Healthcare Acquisition Corporation, 1177 Avenue
of the Americas, Fl 40, New York, New York 10036.
This communication is for informational purposes
only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy, any securities or the solicitation
of any vote in any jurisdiction pursuant to the proposed business combination or otherwise, nor shall there be any sale, issuance or transfer
or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus
meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Jasper Therapeutics Contacts
Jeet Mahal (investors)